Protein degraders gain speed as Arvinas scores landmark approval

<figure><div><img src="https://imgproxy.divecdn.com/muAKX3bazNTOhiHUdkC2HmfksES3Ay-oEQi2NhaFVTQ/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjYtMDUtMDJfYXRfMy4xMS4xOV9QTS5wbmc=.webp"/></div></figure><p>Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.</p>

Kelly Bilodeau · 2026-05-04

Protein degraders gain speed as Arvinas scores landmark approval

Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.

Source: PharmaVoice